



The PHSANZ 13th Annual Scientific Meeting
Future Horizons – Pulmonary Hypertension
24 – 25 October 2024

Day 1: PHSANZ Registry Session
Frangipani Ballroom
Thursday, 24 October 10:00am – 11:15am

Talk	Speaker	Time
Registration & Morning Tea		9:00am-10:00am
Session Chair	Dr John Feenstra	
Welcome	Dr John Feenstra	10:00am-10:05am
ASPIRE Registry: The Good, the Bad, and the Ugly	Prof David Kiely	10:05am-10:25am
Go Deep Update	Prof Werner Seeger	10:25am-10:45am
PHSANZ Registry: Where are we now?	Dr Melanie Lavender	10:45am-11:00am
Questions		11:00am-11:15am
Lunch Break		11:15am-1:00pm

Talk		Time
PHSANZ Registry Committee Meeting (PIs and Registry staff only)		12:30pm – 1:00pm



Day 1: PHSANZ Pulmonary Hypertension Masterclass

Frangipani Ballroom

Thursday, 24 October 1:00pm – 5:00pm

Updates from the World Symposium on Pulmonary Hypertension

Talk	Speaker	Time
Session Chairs	Claire Ellender,	1:00pm-3:30pm
Pathobiology of PAH	Dr David Michail	1:00pm-1:20pm
Role of Genetics and Genomics	Dr Shaun Yo	1:20pm-1:40pm
PAH in Special Circumstances	A/Prof Dom Keating	1:40pm-2:00pm
Risk Stratification	A/Prof Eugene Kotlyar	2:00pm-2:20pm
PAH Treatment Algorithm	Dr Emily Lawton	2:20pm-2:40pm
1 st Session Q&A		2:40pm-3:00pm
Afternoon Tea		3:10pm-3:30pm

Living with PAH

Talk	Speaker	Time
Session Chairs	Hayley Barnes	3:30pm-5:00pm
The patient experience	Jessica Luxford	3:30pm-3:50pm
Developing a national pulmonary hypertension network and patient partnership: the UK experience	Prof David Kiely	3:50pm-4:10pm
Managing the deteriorating patient	Dr Vince Pellegrino	4:10pm-4:30pm
Lung transplantation in PAH	Dr Helen Whitford	4:30pm-4:50pm
Masterclass Q&A		4:50pm-5:00pm



Day 1: Facilitated Poster Session
Frangipani Ballroom
Thursday, 24 October 5:30pm – 6:30pm

Talk	Speaker	Time
Mini Oral Digital Poster Session (5mins with up to 5 questions each)		5:30pm-6:30pm
Triumph of Triads: Selexipag Unveiled in Paediatric Pulmonary Hypertension Triple Therapy	Adam Keighley	
Interim results from the phase 1B and phase 2 TORREY open-label extension (OLE) study of seralutinib in pulmonary arterial hypertension (PAH)	Wendy Stevens	
Pulmonary Hypertension in a Malaysian Population: A 5-Year Retrospective Analysis from a Single-Centre, Single-Discipline; Resource Limited Healthcare Setting Centre	Fatimah Azmah	
Hub-and-spoke PH: First five years at a regional Australian PH centre	Nikkola Sergeant	
Establishing pulmonary hypertension care in Geelong- a year in review	Monica Hatch	
Exercise elicits abnormal pulmonary vascular haemodynamics related to radiologic distribution of chronic thromboembolic pulmonary disease	Anna Beale	
Selexipag in patients with pulmonary arterial hypertension in Queensland	Michael Trotter	
Queensland Experience in Balloon Pulmonary Angioplasty for management of chronic thromboembolic pulmonary hypertension	Shawn Zhenhui Lee	

Cocktail Networking Reception
Frangipani Ballroom
Thursday 24 October 6.30pm – 8.00pm

Proudly sponsored by Platinum Sponsor:



PHARMACEUTICAL COMPANIES OF
Johnson & Johnson



Day 2: Scientific Plenary Sessions
Frangipani Ballroom
Friday 25 October 8:45am – 12:15pm

Talk	Speaker	Time
Registration		8:00am-8:45am
President's Address	John Feenstra	8:45am-8:55am
Session One: Evaluation of PAH	Chairs: Shaun Yo	
Top tips for transthoracic echo	TBC	8:55am – 9:15am
Emerging imaging modalities	Prof David Kiely	9:15am-9:35am
Pro / Con debate: Right Heart Evaluation		
RHC should be the gold standard	A/Prof Andrew Burns	9:35am-9:55am
Cardiac imaging should be the gold standard	Prof David Kiley	9:55am-10:15am
Panel Discussion and Questions		10:15am-10:25am
Morning Tea		10:25am-10:45am
Session Two: PAH in Special Populations	Chairs: Sunaina Parsons, David Youssef	
Managing congenital heart disease in the adult	Dr Vishva Wijesekera	10:45am-11:05am
PAH with ILD in Scleroderma	Dr Wendy Stevens	11:05am-11:25am
Run away and hide or is there light at the end of the tunnel: Management of left heart disease in PAH	Dr Anna Beale	11:25am-11:45am
CTEPH: Beyond PEA and BPA	Dr Hayley Barnes	11:45am-12:05pm
Panel Discussion and Questions		12:05pm-12:15pm
Lunch		12:15pm-1:15pm



Day 2: Scientific Plenary Sessions
Frangipani Ballroom
Friday 25 October 1:15pm – 5:00pm

Talk	Speaker	Time
Session Three: Oral Abstracts (12mins with 3mins questions each)	Chaired by: Rob Carrol Norm Morris	1:15pm-3:00pm
Autonomic reflex drivers of exercise limitation in pulmonary arterial hypertension	Michael Plunkett	1:30pm-1:45pm
Initial Long-term Data from a Phase 3 Open-label Extension Study (ROR-PH-303) Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension (ADVANCE EXTENSION)	John Feenstra	1:45pm-2:00pm
Sustained Benefit With Seralutinib Treatment: A Post-hoc Analysis of the TORREY Open-label Extension	Wendy Stevens	2:00pm-2:15pm
Sexual Dimorphism in Pre-Clinical Models of Pulmonary Arterial Hypertension	Chloe Landy	2:15pm-2:30pm
Prognostic Value of Main Pulmonary Artery Diameter in Pulmonary Arterial Hypertension	Jacob Cao	2:30pm-2:45pm
Afternoon Tea		3:00pm-3:30pm
Session Four: The Future of PAH	Chaired by: Bronwen Rhodes, Helen Whitford	3:30pm-5:00pm
Emerging Therapies	Dr Rob Lewis	3:30pm-3:50pm
PAH Clinical Trial Design	Dr Greg Kier	3:50pm-4:20pm
Post PTE Follow up: A Pragmatic Approach	Prof David Kiely	4:20pm-4:45pm
Panel Discussion and Close Awards – Oral Abstract and Janssen Major Grant	John Feenstra	4:45pm-5:00pm
Sessions Close		5:00pm



PHSANZ Board Meeting and Sponsors Meeting

Orchid Room

Saturday 26 October 8:30am – 1:30pm

Talk	Speaker	Time
PHSANZ Board Meeting (Members only)		8:30am-12:00pm
Lunch		12:00pm-12:30pm
Sponsors Meeting with the PHSANZ Executive		12:30pm-1:30pm



The PHSANZ would like to acknowledge their gratitude to the sponsors of the PHSANZ 13th ASM:

PLATINUM SPONSOR



SILVER SPONSOR



BRONZE SPONSORS



The PHSANZ would also like to acknowledge their valued partners:

